Hyflux Signs Agreement with Changi General Hospital to Conduct First Human Clinical Trials Of ELO Water On Diabetes

15 Feb 2017

Clinical Trial Agreement between Hyflux and Changi General Hospital

Hyflux Ltd (Hyflux) signed an agreement with Changi General Hospital (CGH) on 15 February 2017 to conduct two clinical trials to establish the effectiveness of Hyflux’s ELO Water and ELO Gel on diabetes control and diabetic foot ulcer patients.

The trials will study whether patients with diabetes can obtain better glycaemic control by drinking ELO Water in addition to their ongoing lifestyle and medical treatments, and whether diabetic foot or ankle ulcers can be treated with ELO Water bath and ELO Gel. Dr Joan Khoo, Senior Consultant and Chief of Endocrinology at CGH, is the principal investigator of both trials. Please refer to Annex 1 for details of the trials’ study protocols.

Hyflux is committing up to S$2.5 million in cash and in kind to human clinical trials to further ascertain the scientific merits of ELO Water. ELO Water is created through technology that allows a high level of oxygen to exist in the water in a unique, stable and bound form that is believed to allow quick absorption by the body, restoring its natural balance and enhancing health and overall well-being.

Positive results have been obtained from animal trials of ELO Water conducted overseas. Trials conducted by researchers at Monash University in Australia on transplanted human cancerous tumours in mice showed that ELO Water through oral application was able to be absorbed and penetrated into the tumours, enhancing oxygen levels inside the cancers and inhibiting their growth.

“We have made steady progress in introducing ELO to the wellness market. The partnership between Hyflux and CGH represents our commitment to further ascertain the scientific merits and efficacy of ELO Water and ELO gel on diabetes care. If the trials are successful, it will ultimately improve the quality of life for diabetic patients,” said Ms Olivia Lum, Executive Chairman and Group Chief Executive Officer, Hyflux.

“Diabetes is a significant public health concern for Singapore. Hyflux has come to us with an interesting hypothesis based on animal studies that could help our patients with diabetes. We have thus embarked on this research collaboration to test this hypothesis in a robust scientific way. This collaboration is part of CGH’s commitment to innovation in healthcare,” said Dr Lee Chien Earn, Chief Executive Officer, CGH.

In 2015, International Diabetes Federation reported that 12.8% or 541,600 of Singaporeans aged 20 years to 79 years were reported to have diabetes. The prevalence of Type 2 diabetes in Singapore is forecast to double from 7.3 per cent in 1990 to 15 per cent in 2050.1